Developers
Geoffrey M Lynn, Richard Laga, Patricia A Darrah, Leonard W Seymour, Robert A Seder, etc.
Description of the technology
The efficacy of vaccine adjuvants such as
Practical application
Polymer carriers of TLRa, such as those, used in this technology, represent a diverse and versatile class of adjuvant that can be systematically tuned to achieve the optimal magnitude, quality and spatiotemporal characteristics of innate immune activity required for eliciting antibody and T cell immunity. These polymer carriers and adjuvants, produced with their use, can be applicable and important for applications in preventive and therapeutic vaccines for infections and tumors.
Laboratories
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, (USA)
- Department of Oncology, University of Oxford (UK)
- Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague (Czech Republic)
- Imaging Probe Development Center, National Heart, Lung, and Blood Institute, NIH, Rockville USA)
Links
http://www.nature.com/nbt/journal/v33/n11/full/nbt.3371.html#Publications
- Lynn G.M., et al. «In vivo characterization of the physicochemical properties of
polymer-linked TLR agonists that enhance vaccine immunogenicity." 33.11 Nat Biotechnol., (2015): 1201−1210. - Seder, R.A., Darrah, P.A. & Roederer, M. «
T-cell quality in memory and protection: implications for vaccine design." 8 Nat. Rev. Immunol., (2008): 247–258. - Seymour, L.W. et al. «Hepatic drug targeting: phase I evaluation of
polymer-bound doxorubicin." 20 J. Clin. Oncol., (2002): 1668–1676. - Seymour, L.W., Duncan, R., Strohalm, J. & Kopecek, J. «Effect of molecular weight (Mbarw) of N-(
2-hydroxypropyl )methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats." 21 J. Biomed. Mater. Res., (1987): 1341–135.